Urology Search
Urology Urology
overactive%20bladder
OVERACTIVE BLADDER

Overactive bladder or non-neurogenic overactive bladder is a syndrome characterized by urinary urgency, frequency, nocturia and urgency incontinence.
It is not a disease but a symptom complex that generally is not a life-threatening condition. It is also known as bladder spasms.
Urgency is the complaint of sudden, compelling desire to pass urine that is difficult to deny. It is considered a hallmark symptom of overactive bladder.
Frequency is usually micturition of >7 episodes during waking hours.
Nocturia is the interruption of sleep one or more times because of the need to void.
Urgency incontinence is the involuntary leakage of urine associated with a sudden compelling desire to void.

Surgical Intervention

InterStim Therapy
  • Used in patients with urinary urgency, frequency, urge incontinence and retention
  • A small device implanted under the skin of one of the upper buttocks
  • Works by gently stimulating the sacral nerves to help the bladder function normally
Augmentation Cystoplasty
  • Small piece of tissue from the intestine is added to the wall of the bladder to increase the size of the bladder
  • Done by opening the abdomen and sometimes through the use of laparoscope
  • Consider in patients with non-progressive neurological disorders and impaired bladder storage
Urinary Diversion
  • Procedure is only done if all other options have failed to treat overactive bladder (OAB) symptoms
  • Tubes from the kidneys to the bladder and ureters are routed directly to the outside of your body
Nerve Stimulation
 Sacral nerve stimulation
  • Small pulse generator is implanted under the skin of the buttock to send electrical signals to the nerves that control the bladder
Peroneal nerve stimulation
  • Another pulse generator used to stimulate the nerves controlling the bladder
Editor's Recommendations
Most Read Articles
BMD loss similar between CAB and GnRH agonist monotherapy
14 Mar 2017
Asian prostate cancer patients may show a significant reduction in bone mineral density (BMD) 12 months after androgen deprivation therapy (ADT) with no difference between those on continuous combined androgen block (CAB) and those on gonadotropin-releasing hormone (GnRH) agonist monotherapy, a new study shows.